FDA grants binx health CLIA-Waiver for its first-of-kind binx io platform for chlamydia and gonorrhea testing

Learn More

Lab-quality STI testing in about 30 minutes.

binx is now accepting reservations for the binx io, the first-ever FDA-cleared, rapid, molecular point-of-care platform for the detection of chlamydia and gonorrhea in women and men.

Ready to reserve?

Reserve a spot for access to a binx io for your clinic today.

  • Streamline workflows by offering patients single-visit test-and-treat and ensuring the appropriate antibiotic is used and minimizing patient follow-up
  • Encourage patient adherence to treatment regimens
  • Increase your clinic’s profitability and productivity

Want to know more?

Receive your demo to see how binx can help you deliver better in-clinic patient care while alleviating administrative burdens.

Let’s connect

Be the first to use a binx io in your clinic. You can sign up to reserve your spot now. Reservations are non-binding.

Published literature


The binx health io CT/NG Assay has been cleared by the United States Food and Drug Administration for use with female vaginal swab specimens, collected either by a clinician or self-collected by a patient in a clinical setting, or male urine specimens.

In April 2019, the binx health io CT/NG Assay received CE-marking for both female vaginal swab and male urine samples.